Eli Lilly looks to extend its winning streak over the broader market to 6 years

The drugmaker's ability to further expand available supply of its obesity and weight loss drugs is crucial.

Eli Lilly looks to extend its winning streak over the broader market to 6 years

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. 

Shelby Knowles | Bloomberg | Getty Images

Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street woke up to its massive opportunity in obesity drugs. Six in a row is not out of the question.